Episona announced this week that it has raised $4 million in seed round funding for its at-home male infertility test, Seed. The test, which evaluates epigenetic changes on DNA to predict the risk for male factor infertility and poor embryo quality. The funding will be used to further Seed sales, marketing, and technology development. Seed is a physician-ordered diagnostic which may be used at home or in a fertility clinic and is one of the first non-invasive male infertility diagnostics available on the U.S. market. Read the full press release here.
